mesna ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1711 3375-50-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mesna
  • mercaptoethanesulfonic acid
  • reduced coenzyme M
A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.
  • Molecular weight: 142.19
  • Formula: C2H6O3S2
  • CLOGP: -1.55
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 54.37
  • ALOGS: -1.05
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g Inhal.solution

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 28.13 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 62 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.65 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 20.50 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.36 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1988 FDA BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 513.99 23.35 267 7717 97400 50499740
Encephalopathy 401.76 23.35 163 7821 33548 50563592
Mucosal inflammation 243.11 23.35 121 7863 40021 50557119
Pancytopenia 178.61 23.35 129 7855 83901 50513239
Neutropenia 172.49 23.35 160 7824 147805 50449335
Pyrexia 113.28 23.35 209 7775 379994 50217146
Cystitis haemorrhagic 104.83 23.35 34 7950 3668 50593472
Febrile bone marrow aplasia 87.11 23.35 34 7950 6277 50590863
Neurotoxicity 84.87 23.35 43 7941 14697 50582443
Thrombocytopenia 79.17 23.35 99 7885 127574 50469566
Leukopenia 76.46 23.35 72 7912 67456 50529684
Toxic encephalopathy 73.61 23.35 29 7955 5486 50591654
Cytomegalovirus infection 71.47 23.35 41 7943 17921 50579219
Haematotoxicity 63.58 23.35 29 7955 7866 50589274
Product use in unapproved indication 59.64 23.35 82 7902 115737 50481403
Venoocclusive liver disease 48.55 23.35 20 7964 4241 50592899
Drug ineffective 45.27 23.35 38 7946 819295 49777845
Sepsis 44.32 23.35 77 7907 132848 50464292
Idiopathic pneumonia syndrome 42.34 23.35 10 7974 330 50596810
Bone marrow failure 40.26 23.35 34 7950 27590 50569550
Anaemia 39.85 23.35 108 7876 252348 50344792
Arthralgia 38.20 23.35 11 7973 438691 50158449
Hypokalaemia 37.51 23.35 57 7927 87935 50509205
Aplastic anaemia 37.25 23.35 20 7964 7683 50589457
Polyneuropathy 36.13 23.35 23 7961 12108 50585032
Vena cava thrombosis 35.53 23.35 13 7971 2008 50595132
BK polyomavirus test positive 33.94 23.35 6 7978 43 50597097
Pneumothorax 33.08 23.35 23 7961 14011 50583129
Cytokine release syndrome 32.45 23.35 19 7965 8615 50588525
Amniotic fluid index decreased 32.10 23.35 5 7979 14 50597126
Mitral valve disease 31.61 23.35 12 7972 2054 50595086
Chronic hepatitis B 31.24 23.35 7 7977 182 50596958
Cardiotoxicity 30.54 23.35 17 7967 7010 50590130
Off label use 28.08 23.35 148 7836 474278 50122862
Periorbital cellulitis 27.85 23.35 8 7976 573 50596567
Blood phosphorus decreased 27.64 23.35 13 7971 3776 50593364
Platelet count decreased 26.82 23.35 53 7931 100673 50496467
Multiple organ dysfunction syndrome 26.40 23.35 36 7948 50301 50546839
Pain 26.00 23.35 32 7952 578871 50018269
Hepatitis E 25.74 23.35 9 7975 1220 50595920
Candida sepsis 25.47 23.35 9 7975 1258 50595882
Posterior reversible encephalopathy syndrome 25.16 23.35 20 7964 14908 50582232
Hyperuricaemia 25.04 23.35 13 7971 4667 50592473
Candida test positive 24.72 23.35 8 7976 856 50596284
Aplasia 24.53 23.35 12 7972 3801 50593339
Hepatocellular injury 24.36 23.35 25 7959 25922 50571218
Erosive oesophagitis 23.48 23.35 9 7975 1580 50595560
Cardiorenal syndrome 23.47 23.35 7 7977 572 50596568
Ejection fraction decreased 23.36 23.35 21 7963 18499 50578641

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 536.75 20.94 365 8722 111875 29453565
Encephalopathy 276.70 20.94 151 8936 30892 29534548
Cystitis haemorrhagic 148.83 20.94 56 9031 4786 29560654
Pyrexia 120.63 20.94 269 8818 287353 29278087
Venoocclusive liver disease 110.16 20.94 50 9037 6867 29558573
Neutropenia 95.70 20.94 156 8931 131555 29433885
Mucosal inflammation 94.50 20.94 78 9009 31517 29533923
Pancytopenia 80.96 20.94 113 8974 83055 29482385
Cytokine release syndrome 72.57 20.94 47 9040 13072 29552368
Febrile bone marrow aplasia 71.60 20.94 38 9049 7313 29558127
Aplasia 69.87 20.94 31 9056 4032 29561408
Thrombocytopenia 65.21 20.94 134 8953 134689 29430751
Leukopenia 62.83 20.94 81 9006 55122 29510318
Venoocclusive disease 62.49 20.94 25 9062 2514 29562926
Fanconi syndrome 58.39 20.94 21 9066 1577 29563863
Aplastic anaemia 57.15 20.94 33 9054 7477 29557963
Haematotoxicity 55.18 20.94 31 9056 6668 29558772
Foetal growth restriction 46.94 20.94 23 9064 3743 29561697
Neutrophil count decreased 46.56 20.94 62 9025 43505 29521935
Acute graft versus host disease 45.40 20.94 26 9061 5798 29559642
Oesophagitis 38.91 20.94 31 9056 11892 29553548
Stomatitis 38.40 20.94 52 9035 37061 29528379
Myelosuppression 38.22 20.94 31 9056 12196 29553244
Neurotoxicity 37.36 20.94 33 9054 14580 29550860
Angiodysplasia 35.82 20.94 11 9076 504 29564936
Fusarium infection 32.33 20.94 12 9075 985 29564455
Bone marrow failure 32.33 20.94 41 9046 27408 29538032
Chronic graft versus host disease 31.44 20.94 18 9069 4011 29561429
Fall 31.22 20.94 8 9079 177170 29388270
Septic shock 31.11 20.94 63 9024 62497 29502943
Polyneuropathy 30.18 20.94 27 9060 12125 29553315
Platelet transfusion 27.52 20.94 11 9076 1103 29564337
Death 25.74 20.94 41 9046 342043 29223397
Neutropenic sepsis 25.14 20.94 24 9063 11703 29553737
Agranulocytosis 24.93 20.94 31 9056 20309 29545131
Drug therapeutic incompatibility 24.64 20.94 6 9081 113 29565327
Toxic encephalopathy 24.21 20.94 16 9071 4596 29560844
Herpes zoster reactivation 24.13 20.94 7 9080 263 29565177
Acute graft versus host disease in skin 24.05 20.94 16 9071 4648 29560792
Myocardial infarction 23.67 20.94 3 9084 110293 29455147
Drug ineffective 23.32 20.94 48 9039 363122 29202318
Cytomegalovirus hepatitis 23.22 20.94 7 9080 301 29565139
Combined immunodeficiency 22.56 20.94 5 9082 61 29565379
Anaemia 22.35 20.94 121 8966 200830 29364610
Staphylococcal bacteraemia 22.23 20.94 18 9069 7061 29558379
Pulpitis dental 21.68 20.94 7 9080 378 29565062
Osmotic demyelination syndrome 21.42 20.94 8 9079 668 29564772
Low birth weight baby 21.17 20.94 17 9070 6591 29558849

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 920.75 19.80 569 15129 187088 64295946
Encephalopathy 623.55 19.80 298 15400 58521 64424513
Pancytopenia 280.74 19.80 251 15447 143058 64339976
Mucosal inflammation 268.29 19.80 175 15523 62409 64420625
Cystitis haemorrhagic 242.41 19.80 86 15612 7870 64475164
Neutropenia 233.57 19.80 289 15409 239335 64243699
Pyrexia 208.56 19.80 434 15264 558210 63924824
Febrile bone marrow aplasia 162.99 19.80 71 15627 11184 64471850
Venoocclusive liver disease 144.44 19.80 63 15635 9952 64473082
Thrombocytopenia 123.23 19.80 206 15492 223595 64259439
Leukopenia 117.94 19.80 134 15564 101108 64381926
Haematotoxicity 117.33 19.80 59 15639 12837 64470197
Pseudomonal sepsis 117.26 19.80 45 15653 5127 64477907
Neurotoxicity 106.10 19.80 72 15626 27332 64455702
Secondary immunodeficiency 100.57 19.80 34 15664 2690 64480344
Aplastic anaemia 96.22 19.80 53 15645 13867 64469167
Toxic encephalopathy 89.56 19.80 45 15653 9770 64473264
Aplasia 81.97 19.80 38 15660 6915 64476119
Fanconi syndrome 79.83 19.80 28 15670 2473 64480561
Cytokine release syndrome 74.20 19.80 52 15646 20777 64462257
Venoocclusive disease 73.95 19.80 30 15668 3955 64479079
Bacterial infection 70.15 19.80 54 15644 24896 64458138
Arthralgia 67.45 19.80 13 15685 442247 64040787
Product use in unapproved indication 67.41 19.80 139 15559 176479 64306555
Polyneuropathy 67.01 19.80 48 15650 19846 64463188
Drug ineffective 66.79 19.80 64 15634 840183 63642851
Bone marrow failure 63.62 19.80 68 15630 47884 64435150
Cytomegalovirus viraemia 55.62 19.80 34 15664 10794 64472240
Anaemia 55.55 19.80 210 15488 378470 64104564
Bronchopulmonary aspergillosis 52.98 19.80 41 15657 19044 64463990
Lymphoid tissue hypoplasia 52.81 19.80 14 15684 477 64482557
Off label use 52.71 19.80 297 15401 632509 63850525
Thymus hypoplasia 51.68 19.80 14 15684 519 64482515
Acute graft versus host disease 50.47 19.80 30 15668 9054 64473980
Cytomegalovirus infection 49.77 19.80 53 15645 37146 64445888
Myelosuppression 48.99 19.80 43 15655 23787 64459247
Septic shock 48.73 19.80 90 15608 105347 64377687
Mycobacterium chelonae infection 46.32 19.80 18 15680 2119 64480915
Sepsis 44.41 19.80 140 15558 230201 64252833
Neutropenic sepsis 43.89 19.80 40 15658 23232 64459802
Idiopathic pneumonia syndrome 42.11 19.80 12 15686 537 64482497
Viral infection 37.30 19.80 45 15653 36095 64446939
Neutrophil count decreased 37.05 19.80 67 15631 77129 64405905
Stomatitis 35.74 19.80 81 15617 109524 64373510
Chronic graft versus host disease 35.58 19.80 21 15677 6255 64476779
Disseminated aspergillosis 35.53 19.80 11 15687 657 64482377
Agranulocytosis 35.27 19.80 45 15653 38184 64444850
Oesophagitis 34.71 19.80 34 15664 21596 64461438
Peripheral swelling 34.37 19.80 5 15693 209148 64273886
Angiodysplasia 33.19 19.80 11 15687 818 64482216
Drug hypersensitivity 32.21 19.80 9 15689 237806 64245228
Malaise 31.55 19.80 30 15668 396217 64086817
Acute graft versus host disease in skin 31.36 19.80 20 15678 6835 64476199
Fungal infection 31.10 19.80 40 15658 34211 64448823
Amniotic fluid index decreased 29.94 19.80 5 15693 14 64483020
Clostridium difficile colitis 29.91 19.80 35 15663 27188 64455846
Fusarium infection 29.76 19.80 12 15686 1557 64481477
Renal tubular disorder 28.72 19.80 18 15680 5969 64477065
Fall 28.29 19.80 36 15662 416790 64066244
Platelet transfusion 28.10 19.80 12 15686 1799 64481235
Multiple organ dysfunction syndrome 27.72 19.80 70 15628 101343 64381691
Cystitis viral 27.70 19.80 9 15689 629 64482405
Dizziness 27.32 19.80 39 15659 430124 64052910
BK polyomavirus test positive 27.31 19.80 6 15692 90 64482944
Fatigue 26.93 19.80 93 15605 748637 63734397
Leukoencephalopathy 26.23 19.80 18 15680 6949 64476085
Chronic hepatitis B 25.95 19.80 7 15691 255 64482779
Depersonalisation/derealisation disorder 25.88 19.80 11 15687 1629 64481405
White blood cell count decreased 25.12 19.80 90 15608 157747 64325287
Bacterial sepsis 25.12 19.80 18 15680 7439 64475595
Drug therapeutic incompatibility 24.34 19.80 6 15692 152 64482882
Peripheral sensory neuropathy 24.33 19.80 21 15677 11357 64471677
Cardiotoxicity 24.10 19.80 20 15678 10254 64472780
Staphylococcal bacteraemia 23.96 19.80 20 15678 10335 64472699
Confusional state 23.91 19.80 126 15572 261018 64222016
Rhinovirus infection 23.40 19.80 16 15682 6140 64476894
Hypokalaemia 23.37 19.80 74 15624 121829 64361205
Candida test positive 23.15 19.80 9 15689 1061 64481973
Myocardial infarction 22.96 19.80 6 15692 165815 64317219
Hyperbilirubinaemia 22.85 19.80 27 15671 21178 64461856
Graft versus host disease 22.70 19.80 22 15676 13791 64469243
Candida sepsis 22.66 19.80 11 15687 2217 64480817
Periorbital cellulitis 22.36 19.80 8 15690 748 64482286
Ejection fraction decreased 22.19 19.80 31 15667 28676 64454358
Nasopharyngitis 22.14 19.80 10 15688 196063 64286971
Blood phosphorus decreased 22.09 19.80 15 15683 5690 64477344
Cardiorenal syndrome 21.79 19.80 9 15689 1241 64481793
Tumour lysis syndrome 21.36 19.80 25 15673 19415 64463619
Platelet count decreased 21.27 19.80 89 15609 167622 64315412
Adenovirus infection 21.04 19.80 16 15682 7239 64475795
Amniotic fluid volume decreased 21 19.80 6 15692 271 64482763
Weight increased 20.97 19.80 13 15685 213335 64269699
Pulmonary toxicity 20.78 19.80 17 15681 8544 64474490
Pain 20.37 19.80 68 15630 553443 63929591
Acute kidney injury 20.25 19.80 182 15516 449058 64033976
Haematuria 20.04 19.80 45 15653 60426 64422608
Bladder telangiectasia 19.89 19.80 3 15695 3 64483031
Hypoalbuminaemia 19.87 19.80 23 15675 17651 64465383

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R05CB05 RESPIRATORY SYSTEM
COUGH AND COLD PREPARATIONS
EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS
Mucolytics
ATC V03AF01 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
CHEBI has role CHEBI:23354 coenzymes
MeSH PA D020011 Protective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Testicular Germ Cell Tumor indication
Prevention of Chemotherapy-Induced Hemorrhagic Cystitis indication
Ewing's sarcoma off-label use 76909002 DOID:3369
Burkitt's lymphoma off-label use 118617000
Non-small cell lung cancer off-label use 254637007 DOID:3908
Malignant tumor of head and/or neck off-label use 255056009
Osteosarcoma of bone off-label use 307576001 DOID:3376
Soft or Connective Tissue Sarcoma off-label use
Renal tubular acidosis contraindication 1776003 DOID:14219
Hyperbilirubinemia contraindication 14783006 DOID:2741
Dehydration contraindication 34095006
Fanconi syndrome contraindication 40488004 DOID:1062
Hypokalemia contraindication 43339004
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Kidney excision contraindication 108022006
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Impaired wound healing contraindication 271618001
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Coma contraindication 371632003
Impaired cognition contraindication 386806002
Breastfeeding (mother) contraindication 413712001
Cancer Chemotherapy Induced Hemorrhagic Cystitis contraindication
Polyneuropathies contraindication
Severe Bone Marrow Depression contraindication
Bone Metastases contraindication
CNS Toxicity contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.61 acidic
pKa2 9.77 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019477 VUID
N0000147597 NUI
D01459 KEGG_DRUG
4019477 VANDF
C0000294 UMLSCUI
CHEBI:62955 CHEBI
CHEMBL1098319 ChEMBL_ID
CHEMBL975 ChEMBL_ID
D015080 MESH_DESCRIPTOR_UI
23662354 PUBCHEM_CID
2813 INN_ID
NR7O1405Q9 UNII
DB09110 DRUGBANK_ID
1546354 RXNORM
41498 MMSL
5057 MMSL
d01411 MMSL
002678 NDDF
108821000 SNOMEDCT_US
386922000 SNOMEDCT_US
COM PDB_CHEM_ID
19767-45-4 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1305 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 27 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1307 INJECTION, SOLUTION 1 mg INTRAVENOUS NDA 24 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1307 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 24 sections
MESNA HUMAN PRESCRIPTION DRUG LABEL 1 10019-951 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
MESNA HUMAN PRESCRIPTION DRUG LABEL 1 10019-953 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
Mesna HUMAN PRESCRIPTION DRUG LABEL 1 25021-201 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
Mesna Human Prescription Drug Label 1 63323-733 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 27 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 67108-3565 TABLET, FILM COATED 400 mg ORAL NDA 26 sections
Mesna Human Prescription Drug Label 1 68083-161 SOLUTION 100 mg INTRAVENOUS ANDA 26 sections